Deregulated HOXB7 expression predicts poor prognosis of patients with malignancies of digestive system

Liu, Fang-Teng; Chen, Han-Min; Xiong, Ying; Zhu, Zhengming

doi:10.23736/s0026-4733.17.07325-4

Cited by 2 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, many gastrointestinal tumor biomarkers are reported. However, some of them are confined to the tumor tissues [23–26]. Because the acquisition of the tumor tissue is invasive and quite hard to identify, this limits the application of these markers in the clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Pretreatment Serum Transthyretin Level in Patients with Gastrointestinal Cancers

et al. 2019

View full text Add to dashboard Cite

Background. Many studies have shown the link between the pretreatment serum transthyretin and prognosis in gastrointestinal (GI) cancers. However, based on the conclusion, the initial findings were inconsistent. Hence, this meta-analysis was performed to identify the prognostic values of the pretreatment serum transthyretin in GI cancers. Methods. Previous studies published before November 2018 were collected from a comprehensive literature search of several databases. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were applied in the assessment of the intensity of associations. Also, the publication bias and the robustness of merged data were assessed. All statistical analyses were undertaken using STATA/SE 14.1. Results. The combined data indicated that the pretreatment serum transthyretin level was related to the prognosis in GI cancers. The group with reduced pretreatment transthyretin had a significantly worse overall survival (OS) (HR=1.71, 95% CI: 1.37-2.05). The subgroup analysis for OS further showed the predictive value of transthyretin. In addition, the low serum transthyretin level could be an unfavorable factor for recurrence-free survival (RFS) or progression-free survival (PFS) (HR=1.66, 95% CI: 1.14-2.18) in GI cancers. Conclusion. The low pretreatment serum transthyretin level implies an unfavorable prognosis for patients with GI cancers. The monitoring of pretreatment transthyretin level could contribute to the risk stratification and individualized therapy in GI cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Pretreatment Serum Transthyretin Level in Patients with Gastrointestinal Cancers

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In addition, expression of HOXB7 was also associated with lymph node metastasis and distant metastasis in variate tumors, indicating that the relationship between abnormal expression of HOX family and prognosis of cancer patients worth investigating. [12] The 2 meta-analyses mentioned above only dealt with the relationship between HOXB7 and digestive tumors or cancer metastasis. Considering that more relevant studies with a wider perspective have come out in recent years, we conducted this meta-analysis on the relationship between HOXB7 and clinicopathological characteristics/prognosis of solid cancer patients, aiming to supplement data regarding this issue and provide some clues for clinical practice.…”

Section: Introductionmentioning

confidence: 99%

“…The results showed that high expression of HOXB7 was associated with poor prognosis, as well as advanced clinicopathologic characteristics such as tumor invasion, lymph node metastasis, distant metastasis, and higher TNM stage. In addition, expression of HOXB7 was also associated with lymph node metastasis and distant metastasis in variate tumors, indicating that the relationship between abnormal expression of HOX family and prognosis of cancer patients worth investigating [12] . The 2 meta-analyses mentioned above only dealt with the relationship between HOXB7 and digestive tumors or cancer metastasis.…”

Section: Introductionmentioning

confidence: 99%

High expression of HOXB7 is an unfavorable prognostic factor for solid malignancies

et al. 2022

View full text Add to dashboard Cite

Background: HOXB7 is abnormally expressed in a variety of tumors, but its prognostic value remains unclear due to sample size limitation and outcome inconsistency in previous studies. This meta-analysis was performed to explore the effect of HOXB7 expression on prognoses and clinicopathological factors in range of the whole solid tumors.Methods: PubMed, EMBASE, and Web of Science databases were searched to identify included studies. Hazard ratios (HR) with its 95% confidence interval (CI) and clinicopathological factors were extracted. Subgroup analyses were performed according to histopathological type, tumor occurrence systems, and HOXB7 detection methods.Results: A total of 3430 solid tumors patients from 20 studies (21 cohorts) were included in the meta-analysis. The results showed that high HOXB7 expression was significantly associated with worse survival (overall survival: HR = 1.98, 95%CI: 1.74-2.26, P < .001 and disease-free survival: HR = 1.59, 95%CI: 1.21-2.09, P = .001), more advanced tumor-node-metastasis (TNM) stage (odds ratio [OR]

show abstract

Deregulated HOXB7 expression predicts poor prognosis of patients with malignancies of digestive system

Cited by 2 publications

References 34 publications

Prognostic Value of Pretreatment Serum Transthyretin Level in Patients with Gastrointestinal Cancers

Prognostic Value of Pretreatment Serum Transthyretin Level in Patients with Gastrointestinal Cancers

High expression of HOXB7 is an unfavorable prognostic factor for solid malignancies

Contact Info

Product

Resources

About